Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
HLS Therapeutics Inc. ("HLS" or the "Company") (TSX-V: HLS), a specialty pharmaceutical company specializing in central nervous system and cardiovascular markets, is pleased to announce that it...
HLS Therapeutics Inc. ("HLS" or the "Company") (TSX-V: HLS), a specialty pharmaceutical company specializing in central nervous system and cardiovascular markets, announces that it has received...
REDUCE-IT™ cardiovascular outcomes study of Vascepa®, for which HLS has in-licensed exclusive Canadian rights, exceeded primary endpoint demonstrating an approximately 25% relative risk...
Cardiovascular Death Reduced by 20% Fatal or Nonfatal Heart Attacks Reduced by 31% Fatal or Nonfatal Stroke Reduced by 28% Urgent or Emergent Coronary Revascularization Reduced by 35%...
HLS Therapeutics Inc. ("HLS" or the "Company") (TSX-V: HLS), a specialty pharmaceutical company specializing in CNS and Cardiovascular markets, announces that it will release its third quarter...